Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils - Wikidata - thesis-toulmin - TriplyDB

Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils

Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils

http://www.wikidata.org/entity/Q24651513

about

Mechanisms of Siglec-F-induced eosinophil apoptosis: a role for caspases but not for SHP-1, Src kinases, NADPH oxidase or reactive oxygen Chronic OVA allergen challenged Siglec-F deficient mice have increased mucus, remodeling, and epithelial Siglec-F ligands which are up-regulated by IL-4 and IL-13 Characterization of expression of glycan ligands for Siglec-F in normal mouse lungs Galactose 6-O-sulfotransferases are not required for the generation of Siglec-F ligands in leukocytes or lung tissue Mice deficient in the St3gal3 gene product α2,3 sialyltransferase (ST3Gal-III) exhibit enhanced allergic eosinophilic airway inflammation Developmental, malignancy-related, and cross-species analysis of eosinophil, mast cell, and basophil siglec-8 expression Anti-Siglec-F antibody reduces allergen-induced eosinophilic inflammation and airway remodeling Siglecs and immune regulation Mechanism of Siglec-8-mediated cell death in IL-5-activated eosinophils: role for reactive oxygen species-enhanced MEK/ERK activation Siglec-F-dependent negative regulation of allergen-induced eosinophilia depends critically on the experimental model.Eosinophil survival and apoptosis in health and disease.What targeting eosinophils has taught us about their role in diseases.Siglec-mediated regulation of immune cell function in disease.Polymorphisms in the sialic acid-binding immunoglobulin-like lectin-8 (Siglec-8) gene are associated with susceptibility to asthma.Novel targeted therapies for eosinophil-associated diseases and allergy The schistosome glutathione S-transferase P28GST, a unique helminth protein, prevents intestinal inflammation in experimental colitis through a Th2-type response with mucosal eosinophils.Human versus mouse eosinophils: "that which we call an eosinophil, by any other name would stain as red".Non-invasive optical imaging of eosinophilia during the course of an experimental allergic airways disease model and in response to therapy.Role of siglecs and related glycan-binding proteins in immune responses and immunoregulation The role of lung epithelial ligands for Siglec-8 and Siglec-F in eosinophilic inflammation.Early murine T-lymphocyte activation is accompanied by a switch from N-Glycolyl- to N-acetyl-neuraminic acid and generation of ligands for siglec-E Critical role of the neutrophil-associated high-affinity receptor for IgE in the pathogenesis of experimental cerebral malaria Additive anti-allergic effects of anti-interleukin-33 and anti-Siglec-F treatments in a murine model of allergic asthma.Granulocyte Macrophage Colony-Stimulating Factor-Activated Eosinophils Promote Interleukin-23 Driven Chronic Colitis Expression and preliminary functional analysis of Siglec-F on mouse macrophages.IL-33-Induced Cytokine Secretion and Survival of Mouse Eosinophils Is Promoted by Autocrine GM-CSF Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions.Novel targeted therapies for eosinophilic disorders Cyclophilin D regulates necrosis, but not apoptosis, of murine eosinophils."Siglec"ting the allergic response for therapeutic targeting.Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors.Basic and clinical immunology of Siglecs Control of lung defence by mucins and macrophages: ancient defence mechanisms with modern functions.Siglecs as targets for therapy in immune-cell-mediated disease.Siglec-F inhibition reduces esophageal eosinophilia and angiogenesis in a mouse model of eosinophilic esophagitis.Siglec-8 and Siglec-F, the new therapeutic targets in asthma.CD33-related siglecs as potential modulators of inflammatory responses.Targeting eosinophils in allergy, inflammation and beyond.Clinical implications and pathogenesis of esophageal remodeling in eosinophilic esophagitis.Eosinophils in the lung - modulating apoptosis and efferocytosis in airway inflammation.

P2860

Q21132992-3B8523EA-1AC7-44FC-A31D-A365014EBB67 Q21284418-612CFB70-D2E2-4A44-BD07-DF147123104A Q24608549-106FE497-1CA2-4758-8E1D-0A229F5F9586 Q24622257-03180390-C1EF-49FB-A5D8-1D27A5F05F62 Q24624727-3DC2F063-01A8-4B25-8A78-6DF86B5C93F4 Q24634555-039BD869-C95D-41FA-9CF9-D9358E82C05D Q24645925-ECE0F22A-2F45-4E0E-AED6-7B0F7E494364 Q26992091-FCD6C301-13D8-47EE-ADD4-1F917FE5B628 Q28290873-93828666-8CB6-49FC-AB05-F322535D97CC Q33710652-250C6756-D480-4434-B7A0-4A8FD6887666 Q33758139-2EFFE516-47C4-4B5C-A891-EDEE79B5025A Q33987218-6C32C64D-7B77-4A95-AE33-E9B09FF672A9 Q34314957-06080B53-90E3-4957-9F70-181C0667EC6F Q34329191-7C2901F4-2284-4D7E-A427-278347845A26 Q34444620-A492AEEB-1E6E-499A-B0AE-6F820850A11D Q34485066-4D533A46-4CE2-44F5-B618-ADF08EFED88C Q34641855-51C7A50E-A480-476C-862C-8C2AC852BAE1 Q35108579-8AE630C1-843D-4C41-900F-0C3A03FA089C Q35164415-3CF4DBB6-3ADB-4491-9366-AE50614B025D Q35222976-D96CD804-32AA-469F-B743-67BD414EC9F9 Q35266949-9D15E213-7A05-490A-89FA-EC6BD047DE50 Q35441422-C44C23D0-8064-4621-B853-A2E915E92527 Q35631650-EBDFD1E9-36A7-4E6F-BBED-B180E2D1968A Q35898996-C6691D42-672F-483D-891C-1056CD8FA3BC Q35946412-0EC749D5-9BFE-49E5-AAD6-535FEA08C31D Q36150043-D7A8981D-283C-481B-9B3C-476B80A42EC7 Q36655884-BA77F74B-0794-4DA4-9B4B-DA98A755DB25 Q36763565-3636CDAE-2020-4126-89FF-CD32FA085AB6 Q36811319-E356BFE1-33FF-4774-96CB-9AEA1680B23C Q36843245-18314FC6-9492-40BD-BF1D-AA93DD92E297 Q37343465-AD7D4859-F3F4-4DEE-882E-1B7B9CC4CFEC Q37348437-CF1BC5A3-BE1F-4CBB-9750-274ABD717680 Q37431918-85AAC9CB-743E-4681-BE62-5BEFC41FBF07 Q37440061-E3344613-88B0-4226-8965-33198190BF67 Q37693833-3023366C-57E5-4603-837C-3C48E0721554 Q37983131-AA3E4EA2-45EA-410F-B7F2-CEF3B5207707 Q37986851-9EBDF017-9FC4-43B4-AB8F-921A02ABB947 Q38075409-2C4F95FB-AAF9-42D2-91DF-201C66E11862 Q38210619-F97A6526-E16A-4153-9262-EE57D8885DB0 Q38234940-AEAA1297-3EB3-457C-AE7D-C6DC002EF51A

P2860

Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils

http://www.wikidata.org/entity/Q24651513

description

2008 nî lūn-bûn

@nan

2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils

@ast

Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils

@en

Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils

@nl

type

label

Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils

@ast

Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils

@en

Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils

@nl

prefLabel

Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils

@ast

Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils

@en

Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils

@nl

P1433

Q24651513-9D200959-D81F-49C4-8B42-E8F23A74CDAF

P1476

Q24651513-E67E1D1E-583B-453F-8341-3738D7C60A55

P2093

Q24651513-07D926C4-562E-4A93-8960-C910741A8FE8

Q24651513-3C3AB6B9-82D3-4080-BD28-D31424D9728F

Q24651513-51A7E565-4A76-4F0E-A834-4B25A67E27F1

Q24651513-5D8A0E3F-3747-4062-BD6B-012AE3E49475

Q24651513-C0865CFE-F8C0-4EBE-B34F-27137F6F4043

Q24651513-C36ECACC-65A9-4937-A3DA-091D3334147E

Q24651513-CF9C5B29-231F-4F33-AA26-930B0E74B161

Q24651513-E43307F0-3AFF-4F04-8C38-EBEF461DC738

P2860

Q24651513-0273E102-356A-45F4-BD0C-C492EACB5CD6

Q24651513-071E7137-064F-44AC-88B0-2C4EDAC91F0B

Q24651513-17F9BD56-F81A-47AB-8725-0FCF94A7FC63

Q24651513-270DC1EE-21F4-4C8A-BAEE-619B455D206A

Q24651513-4EC7A2F6-0D23-461E-BE34-5B93B7868A28

Q24651513-66F68571-61CB-435C-837B-F34BE6E62267

Q24651513-6AFEB3C5-2CEA-4B3F-A1CE-EDE6027B6314

Q24651513-6F79B6D4-7CC4-41D2-8C54-59E81B6B2349

Q24651513-86F85B0B-1E09-48EF-964D-B2DC38CBC4FA

Q24651513-A4C97451-F435-42A8-B9FE-B538B37DA86C

P304

Q24651513-6EBED792-02CF-4898-A4B0-B6BBB7A76B54

P31

Q24651513-90798984-95ED-4BA0-9E70-2D36F5E9966E

P3181

Q24651513-C5244DB5-2111-498D-9963-4C9949087FD0

P356

Q24651513-D408D63D-BC9C-4A98-839B-0197805E457C

P407

Q24651513-3F6E979F-4B7D-4E19-A1A5-3C197FEDFEE6

P433

Q24651513-DA64E999-943A-4141-A6CA-0298A7176010

P478

Q24651513-9B7D7D3D-ADA1-4B80-90E6-FDF471275B83

P50

Q24651513-B45A1611-F177-476D-ABDE-36897832A556

P577

Q24651513-360EDE36-055A-4305-8A55-49570433B42C

P5875

Q24651513-C0A9BD74-50BD-49F3-9DAF-B14F016BFF26

P698

Q24651513-984CF809-236B-44BD-B547-E2FB8286CC3B

P921

Q24651513-63732160-2C1D-4198-8E99-B2F6548BD09E

P932

Q24651513-C3FC67E1-995C-46F5-A719-ABC3E279489A

P3181

P356

J.1398-9995.2008.01709.X

P1433

P1476

Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils

@en

P2093

B S Bochner

http://www.w3.org/2001/XMLSchema#string

C Jones

http://www.w3.org/2001/XMLSchema#string

K D Cromie

http://www.w3.org/2001/XMLSchema#string

M E Rothenberg

http://www.w3.org/2001/XMLSchema#string

M L McBride

http://www.w3.org/2001/XMLSchema#string

N Zimmermann

http://www.w3.org/2001/XMLSchema#string

S A Hudson

http://www.w3.org/2001/XMLSchema#string

Y Yamada

http://www.w3.org/2001/XMLSchema#string

P2860

Siglec-8. A novel eosinophil-specific member of the immunoglobulin superfamily

Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome

Defining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophils

Interleukin-5 priming of human eosinophils alters siglec-8 mediated apoptosis pathways

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells, and basophils

Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis

Mouse Siglec-F and human Siglec-8 are functionally convergent paralogs that are selectively expressed on eosinophils and recognize 6'-sulfo-sialyl Lewis X as a preferred glycan ligand

Inhibition of FcepsilonRI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement

Siglecs--the major subfamily of I-type lectins

P304

1156-1163

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3256238

http://www.w3.org/2001/XMLSchema#string

P356

10.1111/J.1398-9995.2008.01709.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P50

Paul R. Crocker

P577

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23167698

http://www.w3.org/2001/XMLSchema#string

P698

18699932

http://www.w3.org/2001/XMLSchema#string

P921

P932

2726770

http://www.w3.org/2001/XMLSchema#string